Complement Activation As A Therapeutic Target And Clinical Biomarker For Parkinson's Disease
Funder
National Health and Medical Research Council
Funding Amount
$497,941.00
Summary
Parkinson’s disease is the second most common neurological disease in Australia, yet there is no treatment to slow disease progression. Our study is investigating inflammation within the brain as a major contributing factor in Parkinson’s disease. We will examine this inflammatory pathway in human patients suffering from Parkinson’s, and will test a novel anti-inflammatory drug in animal models of Parkinson’s disease, in order to identify a novel treatment to reduce disease pathology.
Metal-mediated Mechanisms And Therapeutic Approaches For Treating Brain Injury Across Age
Funder
National Health and Medical Research Council
Funding Amount
$1,229,769.00
Summary
This grant will examine the role of zinc and iron in the neuronal changes that occur following brain injury, with a specific focus on the role of these metals in functional outcomes. We will also examine how the role of these metals changes across the normal lifespan, and also whether these metal changes are consistent across different types of brain injury. Finally, we will examine the therapeutic potential of zinc- and iron-targeted compounds.
Therapeutic Targeting Of Neuroinflammation To Slow The Progression Of Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
My research has identified key components of our immune system, that can worsen disease in conditions such as Parkinson’s disease and motor neuron disease. I hope that exploring these components in animal models, and patients suffering from these diseases, my group can identify new therapeutic drug candidates that can be progressed in clinical trials. Ultimately, this may lead to new treatments to reduce disease burden in patients suffering from these neurodegenerative conditions.
The Role Of BMP Signalling During Chronic Demyelination And Myelin Repair
Funder
National Health and Medical Research Council
Funding Amount
$67,381.00
Summary
Multiple sclerosis (MS) is the most common neurodegenerative disease affecting young adults. It is a disease that kills myelin cells, which are important support cells for neurons and critical for neuronal function. This research investigates the role of a specific signaling pathway with respect to myelin cell production and repair with the ultimate aim of identifying regenerative therapeutics for MS.
Characterisation And Modelling Of Schizophrenia-associated Dysregulation Of MiR-137 Expression
Funder
National Health and Medical Research Council
Funding Amount
$581,661.00
Summary
We have identified mutation-associated changes in the expression of a non-coding microRNA gene in the cerebral cortex in schizophrenia. This gene, known as MIR137, functions by repressing hundreds of target genes and therefore has major implications for schizophrenia. The project will identify the genetic mechanism affecting the expression of MIR137, and determine the biological and behavioural implications of this change in the context of schizophrenia.
Cell Death In The Retina: Analysing The Switch That Triggers Dependency On Target-derived Trophic Factors
Funder
National Health and Medical Research Council
Funding Amount
$428,414.00
Summary
Construction of the developing nervous system in the embryo involves the creation of nerve cells and their connections, but also involves loss of a proportion of these cells prior to maturation. We will study this process of cell death and how developing nerve cells switch on their dependency to survival factors. In so doing we will better understand what happens when brain development goes wrong and also devise new ways to protect nerve cells in the injured or degenerate adult nervous system.
The Role Of Metals In Healthy Brain Aging: Identification Of Novel Compounds To Prevent Age-related Cognitive Decline
Funder
National Health and Medical Research Council
Funding Amount
$789,733.00
Summary
This grant will explore the basic mechanisms that underlie normal learning and memory. Specifically, we are focussing on how the modulation of metal levels may occur with age, and how this may cause or at least contribute to age-related cognitive impairment. We are also examining a novel therapeutic compound for the treatment of cognitive dysfunction. This work will have implications for both normal and pathological ageing.
Electrical Stimulation With A “Random Noise” Pattern: A New Approach For The Treatment Of Depression
Funder
National Health and Medical Research Council
Funding Amount
$523,160.00
Summary
This study is a world first, examining the use of a novel technology to treat depression by stimulating the brain mildly and non invasively. The study will examine the effectiveness of a 4-week course of Transcranial “Random Noise” Stimulation to treat depression, and will also measure whether improvement in mood is accompanied by a restoration of brain plasticity or adaptability.
Biomaterials For The Direct Reprograming Of Reactive Astrocytes Into Functional Neurons
Funder
National Health and Medical Research Council
Funding Amount
$630,500.00
Summary
We will employ peptide inspired hydrogel nanoscaffolds that can be injected into a brain lesion as a single injection to provide chemical and physical support for the surrounding cells. We will utilize various modifications to these materials to reprogram inflammatory cells into neurons, whilst also promoting the survival, maintenance and growth of existing neurons to encourage repair.
Molecular Imaging To Advance Treatment Of Dementia
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Molecular imaging using a scan technique called positron emission tomography, enables detection and measurement of specific pathological features of disease such as the amyloid plaques of Alzheimer’s disease. This project will develop this technology for other aspects of brain disorders including dementias, Parkinson’s disease, traumatic brain injury and schizophrenia and use it to assist development of therapies and improve clinical diagnosis nation wide.